Michael W. Boyer

Michael W. Boyer, MD

Languages spoken: English

Academic Information

Departments Adjunct - Pediatrics

Dr. Boyer is currently the Director of the University of Utah Blood and Marrow Transplant Program, which encompasses both adult and pediatric bone marrow transplant, with clinical services at the Huntsman Cancer Institute (Clinic 2C) and at Primary Children's Medical Center. He is also the Medical Director for the University of Utah Cell Therapy Facility.

For questions regarding Dr. Boyer's adult practice at the Huntsman Cancer Institute, or for questions about any of our clinical programs and for assistance identifying the right Hematology specialist for you or your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at (801) 587-4652, or www.huntsmancancer.org

For questions regarding Dr. Boyer's pediatric practice and the Blood and Marrow Transplant Program at Primary Children's Medical Center, please call (801) 662-4830, or please feel free to contact Stephanie Mortensen, RN-C, Coordinator at Stephanie.Mortensen@imail.org or Shawnda Ussery, RN-C, Coordinator at Shawnda.Ussery@imail.org

Education History

Undergraduate Indiana University
 BS
Professional Medical Indiana University
 MD
Residency University of Minnesota
 Resident
Fellowship University of Minnesota
 Fellow
Research Fellow University of Minnesota
 Research Fellow

Selected Publications

Journal Article

  1. Adamkiewicz TV, Bray R, Boyer MW, Yeager AM (2005). Feasibility of identification of unrelated cord blood units matched at high resolution HLA loci for transplantation in patients with sickle cell disease.(in press). Journal of pediatric hematology/oncology,
  2. Adamkiewicz TV, Szabolcs P, Haight A, Baker KS, Staba S, Kedar A, Chiang KY, Krishnamurti L, Boyer MW, Kurtzberg J, Wagner JE, Wingard JR, Yeager A (2007). Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatric transplantation, 11(6), 641-4.
  3. Kim JH, Goulston C, Zangari M, Tricot G, Boyer MW, Hanson K (2014). Impact of a change in antibacterial prophylaxis on bacteremia and hospitalization rates following outpatient autologous peripheral blood stem cell transplantation for multiple myeloma. Transplant infectious disease, 16(3), 421-9.
  4. Caldas H, Jaynes FO, Boyer MW, Hammond S, Altura R (2006). Survivin and Granzyme B-induced apoptosis, a novel anticancer therapy. Molecular cancer therapeutics, 5(3), 693-703.
  5. Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W, Boyer MW, Carraway HE, Coccia PF, Coutre SE, Cultrera J, Damon LE, DeAngelo DJ, Douer D, Frangoul H, Frankfurt O, Goorha S, Millenson MM, O'Brien S, Petersdorf SH, Rao AV, Terezakis S, Uy G, Wetzler M, Zelenetz AD, Naganuma M, Gregory K (2012). Acute lymphoblastic leukemia. Journal of the National Comprehensive Cancer Network, 10(7), 858-914.

Abstract

  1. Kalpatthi R, Nicol K, Hendey L, Boyer M (2005). In vitro cultured allogeneic cytotoxic T cells mediate hematopoietic GVHD without gut GVHD despite expression of functional LPAM (alpha4 beta7 integrin). Blood, 106(379a),
  2. Boyer MW, McQuown K, Hendey L, Cipkala D (2005). Role of IL-2, IL-7, IL-15, and SDF-1¿ in T cell mediated graft-vs-leukemia against human acute lymphoblastic leukemia in a NOD/scid chimeric mouse model. 27(464),
  3. Boyer MW, McQuown K, Hendey L, Cipkala D (2005). Role of IL-2, IL-7, IL-15, and SDF-1a in T cell mediated graft-vs-leukemia against human acute lymphoblastic leukemia in a NOD/scid chimeric mouse model. 27(464),
  4. Rondelli D, Boyer MW, Isola LM, Shore T, Bacigalupo A, Klisovic RB, Marchioli R, Goldberg JD, Hoffman R, Silverman LR and Myeloproliferative Disorders Research Consortiu (2010). First prospective study of allogeneic peripheral blood stem cell (PBSC) transplantation in patients with myelofibrosis in the United States: Interim analysis of MPD-RC 101 protocol. 28(6535),